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Key messages
What is already known about this subject?
 ► clinical remission is achieved in only a minority of 
patients with rheumatoid arthritis and sustained 
drug-free remission remains rare. additionally, re-
sponse to treatment varies in rheumatoid arthritis.
What does this study add?
 ► through industry-academic collaboration, individual 
patient-level data on 3290 patients from the non-bi-
ological arms of 18 trials were collated and resulted 
in the identification of predictors of remission and 
longitudinal disease activity patterns.
 ► Differential effects of physical/functional and mental 
well-being on 6-month Disease activity Score 28 re-
mission were seen between methotrexate-naïve pa-
tients with early disease and those with established 
disease and prior methotrexate exposure at entry.
 ► through novel latent class methodology, three lon-
gitudinal patterns of disease activity were discerned 
in both the baseline methotrexate-naïve and metho-
trexate-exposed rheumatoid arthritis patient groups.
How might this impact on clinical practice?
 ► latent class methodology allows both prediction of 
trajectory membership and future disease course 
using outcome and covariate information, and can 
inform trial selection and patient management.
AbstrAct
Objectives to identify predictors of remission and disease 
activity patterns in patients with rheumatoid arthritis (ra) 
using individual participant data (iPD) from clinical trials.
Methods Phase ii and iii clinical trials completed between 
2002 and 2012 were identified by systematic literature 
review and contact with UK market authorisation holders. 
anonymised baseline and follow-up iPD from non-
biological arms were amalgamated. Multiple imputation 
was used to handle missing outcome and covariate 
information. random effects logistic regression was 
used to identify predictors of remission, measured by the 
Disease activity Score 28 (DaS28) at 6 months. novel 
latent class mixed models characterised DaS28 over time.
Results iPD of 3290 participants from 18 trials were 
included. Of these participants, 92% received methotrexate 
(MtX). remission rates were estimated at 8.4%(95%ci 
7.4%to9.5%) overall, 17%(95%ci 14.8%to19.4%) for 
MtX-naïve patients with early ra and 3.2% (95% ci 
2.4% to 4.3%) for those with prior MtX exposure at entry. 
in prior MtX-exposed patients, lower baseline DaS28 
and MtX reinitiation were associated with remission. in 
MtX-naïve patients, being young, white, male, with better 
functional and mental health, lower baseline DaS28 and 
receiving concomitant glucocorticoids were associated 
with remission. three DaS28 trajectory subpopulations 
were identified in MtX-naïve and MtX-exposed patients. 
a number of variables were associated with subpopulation 
membership and DaS28 levels within subpopulations.
Conclusions  Predictors of remission differed between 
MtX-naïve and prior MtX-exposed patients at entry. latent 
class mixed models supported differential non-biological 
therapy response, with three distinct trajectories observed 
in both MtX-naïve and MtX-exposed patients. Findings 
should be useful when designing future ra trials and 
interpreting results of biomarker studies.
BaCkgROund
Rheumatoid arthritis (RA), an inflammatory 
disease of synovial joints, leads to functional 
disability and reduced quality of life. Currently, 
there is no cure but many studies confirm the 
benefit of early and intensive treatment on 
long-term outcome.1 2 Nonetheless, clinical 
remission is achieved in only a minority of 
patients3 4 and sustained drug-free remission 
remains rare.5 6
Response to treatment varies in RA. Clinical 
trials report average disease activity change, 
but within treatment arms there is hetero-
geneity; some patients entering clinical 
remission and some failing to respond. Back-
ground disease activity also fluctuates, with 
some patients demonstrating an initial short-
term improvement then either relapsing 
or plateauing with still relatively active 
disease irrespective of treatment. Moreover, 
conventional synthetic disease-modifying 
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antirheumatic drugs (csDMARD) have slow onset of 
action. Given that prolonged periods of uncontrolled 
disease activity lead to joint damage and disability, a 
major unmet need is to identify patient-level predictors 
of response in order to identify patients with differing 
patterns of response over time (ie, types of patients with 
a greater or lesser chance of responding). Such infor-
mation could guide treatment choices, saving both time 
and money in achieving sustained disease control; and 
improve the efficiency of clinical trials.
The Rheumatoid Arthritis (RA-MAP) Consortium is 
a UK industry-academic partnership funded jointly by 
the Medical Research Council and the Association of 
the British Pharmaceutical Industry. RA-MAP’s goal is to 
investigate clinical and biological predictors of disease 
outcome in RA, by bringing together experts in basic, 
clinical, therapeutic development and biostatistical 
research.7 One RA-MAP work stream investigated clin-
ical predictors of remission and response by collation of 
individual participant data (IPD) from the non-biolog-
ical arms of randomised controlled clinical trials (RCT). 
The aims were to identify predictors of response and to 
identify disease trajectory subpopulations; and then use 
the findings to inform study design and analysis of future 
studies.
MeTHOds
Identification of relevant studies and study selection
Potential studies were identified by systematic literature 
review (final search: 13 March 2012) from MEDLINE, 
EMBASE, PubMed, Ovid, Web of Science, UK Clinical 
Research Network Portfolio Database (http:// public. ukcrn. 
org. uk/),  ClinicalTrials. gov (https:// clinicaltrials. gov) and 
the National Research Register. Searches combined MeSH 
terms for RA, study type (eg, ‘randomised controlled trial’) 
and biological and non-biological DMARDs. Additionally, 
chief investigators of known academic-led clinical trials 
completed between 2002 and 2012, involving UK patients, 
were contacted. Current UK market authorisation holders 
for non-biological and biological DMARDs were also sent 
a survey via their RA-MAP representative to identify addi-
tional trials and seek information on availability of IPD 
from clinical trials coordinated in the UK or which enrolled 
UK subjects.
Assessment of trials’ eligibility for inclusion was 
performed independently by the study coordinator 
and principal investigator (DS). Lack of consensus was 
resolved through discussion with the trial’s chief investiga-
tor(s), industry sponsor or referral to study publications.
A second literature search was conducted to identify 
known predictors of remission in RA. This informed the 
request for baseline data items.
Owners of suitable trial data sets were approached via 
the RA-MAP representative for access to data on requested 
variables for all (or a random 80% of) participants in 
non-biologic arm(s) of these trials. The inclusion criteria, 
trials obtained and data requested are detailed in online 
supplementary material. Eligibility of data sets relied on 
the original informed consent allowing data sharing.
data collection, management and harmonisation
Deidentified data were transferred to the coordinating 
centre, and further anonymisation added through gener-
ation of new unique study identifiers.
Data received were checked for internal consistency, 
with queries referred back to data owner/supplier. 
Data were harmonised across trials (ie, given single 
variable name, standardisation of unit measurement, 
similar coding of variables when possible) to a standard 
format for incorporation into a central database. The 
end product was a pooled database of IPD from trials 
received. Although a common set of items was requested, 
some trials, by design, had not collected all items, or when 
collected, differed in form/construct or level of detail.
derived disease activity measure and remission definition
Where possible Disease Activity Score 28 (DAS28) was 
derived using the four individual components of eryth-
rocyte sedimentation rate (mm/hour), patient global 
assessment of disease activity (0–100mm visual analogue 
scale (VAS)) and 28-tender and 28-swollen joint counts.8 
If patient global assessment was not supplied as a VAS, the 
three-component DAS28 was calculated.8 If direct deriva-
tion of DAS28 was not possible then supplied DAS28 was 
used or the transformation of van Gestel et al9 applied 
to convert original DAS10 11 to DAS28. Clinical remission 
was defined as DAS28<2.6.12
sample size evaluation
Initial sample size calculation considered a remis-
sion model with 25 significant effects. For simplicity, it 
assumed that these effects arose from continuous varia-
bles that remained statistically significant when dichoto-
mised. A clinically worthwhile detectable difference in 
remission rates between two groups, formed by median 
dichotomisation of any predictor, was taken as 4% (eg, 
6% remission rate for group below median vs 10% for 
group above median; giving an overall remission rate of 
8%). Assuming a significance level of 0.2% (accounting 
for multiple testing), a total sample size of 4218 or 2942 is 
calculated for 95% or 80% power, respectively.
The above scenario was conservative because (1) fewer 
significant effects could be expected; (2) dichotomisa-
tion results in efficiency losses; (3) a 4% difference was 
considered small; and (4) strict significance level of 0.2% 
was chosen. It was anticipated that sample sizes above 
2500 would be sufficient to achieve the work stream’s 
aims.
statistical methods
The main analyses were based on coprimary outcomes 
of clinical remission at 6 months (within a 22–26-week 
window) and DAS28 measured longitudinally. One trial, 
with 12-week follow-up, was excluded from analyses of 
remission at 6 months but included in analyses of DAS28 
over time. Clinical remission was estimated overall, and 
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separately for methotrexate-naïve (MTX-naïve) entry 
subjects and those with prior MTX exposure (MTX-ex-
posed). The MTX-exposed group consisted of those 
on background MTX at trial entry and those who had 
discontinued MTX.
To identify predictors of remission, (multilevel) 
random effects logistic regression models (with trial-level 
random effects) stratified by baseline MTX exposure 
were considered. If heterogeneity across trials was insub-
stantial then trial-level random effects were removed. 
The base model focused on known predictors of remis-
sion and potential confounders with limited missing 
information.13–15 It considered the effect of age, sex, 
ethnicity, disease duration, DAS28, rheumatoid factor 
(RF) status and RA medication (both prior exposure and 
as part of study treatment protocol) at baseline. Baseline 
DAS28 and history of RA medication were also included 
to adjust for differences in the trial populations due to 
differing inclusion criteria. Screening models considered 
separate effects of other potential baseline predictors 
introduced into the base model. Multivariate models 
were then built using variables identified as important at 
screen and forward selection.
Longitudinal latent class mixed models, stratified by 
MTX exposure at baseline, were used to (1) characterise 
DAS28 over time (restricted to 1-year follow-up), (2) 
adjust for potential predictors, (3) incorporate within-pa-
tient correlation, and (4) identify cluster trajectories of 
clinically important subpopulations.16 Fixed and random 
patient-level intercepts, linear and quadratic effects were 
considered for linear mixed models fitted within latent 
classes. These random effects were nested within trial. 
Trial-level random effects were considered, but removed 
when found inconsequential. (Relative) entropy was 
calculated to assess the ability of each model to classify 
individuals into latent classes.17 Higher values of entropy 
indicate better classification of individuals.
Sporadically and systematically missing baseline 
covariate and missing outcome information at attended 
visits were imputed using multivariate imputation by 
chained equations,18 19 under the missing at random 
assumption. The hierarchical/multilevel structure (ie, 
visits within patient, patients within trial) was respected 
where possible. Twenty imputed data sets were created, 
analysed and results pooled using Rubin’s rules.20
All statistical analyses were performed in R statistical 
software.21 R packages lme4,22 mice23 and lcmm24 were used 
for the various analyses.
ResulTs
systematic search and inventory of trials survey
We identified 63 trials to include in the inventory (online 
supplementary table 1). Sixty trials were industry spon-
sored (54 from RA-MAP partners) and three academic 
(from RA-MAP partners). Partial or complete informa-
tion from study sponsors or publicly available sources 
was collated for 54/63 trials. There were 8778 patients 
in non-biological arms of these 54 trials with estimated 
6-month remission rate of 8.2%. This estimate informed 
study sample size (see the Methods section).
Trials received
Patient-level data from non-biological arms of 19 trials 
were provided by six industry and two academic RA-MAP 
partners (see online supplementary table 1). One trial 
was excluded as it recruited patients with early inflam-
matory polyarthritis. Patients in the included trials (all 
started before 2010) met the 1987 American College 
of Rheumatology RA classification criteria.25 Data for 
3290 participants from the combined non-biological 
arms of these 18 trials were obtained. Patient numbers 
from these trials ranged from 50 to 467. Non-biological 
assigned treatments included (1) placebo, (2) MTX or 
other csDMARD monotherapy, or (3) MTX in combina-
tion with another csDMARD and/or with glucocorticoid. 
Placebo-treated patients received either (1) placebo in 
addition to background RA medication; (2) placebo 
alone (with RA medication discontinued prior to trial 
start); or (3) placebo alone (with no prior RA medica-
tion; ie, RA medication naïve). Further information on 
planned duration of RCT phase, inadequate response 
to csDMARDs, biological intervention, and primary and 
secondary efficacy outcomes related to disease activity 
are reported in online supplementary table 1. No data 
on patients treated in the biological arms of these trials 
were requested or received.
Patient characteristics
The baseline demographic and disease characteristics of 
included patients are summarised in table 1. Only three 
trials provided information on anti-citrullinated protein 
antibody status. The mean baseline DAS28 (with SD) was 
6.5(1.1).
Fifty-four per cent of patients were on background 
MTX at start, 35% were MTX-naïve and 11% had prior 
MTX exposure (MTX discontinued). Ninety-two per 
cent of participants were either randomised to MTX or 
were on background MTX that continued. Twelve per 
cent was randomised to or continued other csDMARDs. 
The corresponding percentage for glucocorticoids was 
27%. The majority of MTX-naïve patients at entry (93%) 
were randomised to MTX. Fifty-two per cent of those 
who discontinued MTX were randomised to MTX reini-
tiation. A majority of them were viewed as having already 
demonstrated lack of adequate MTX response.
The 1137 patients who were MTX-naïve at trial entry 
had substantially shorter median symptom duration than 
the 2148 patients with prior MTX exposure (8 months vs 
7 years, p<0.0001); confirming the fact that the former 
corresponded to those with early RA.
Clinical remission at 6 months
Overall 6-month remission rate was estimated at 
9.6%(95%CI 8.4%to10.9%) based on 2275 patients 
for whom 6-month remission could be defined from 
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observed data. After multiple imputation, a 6-month 
remission rate of 8.4%(95%CI 7.4%to9.5%) was esti-
mated based on 2766 patients who had attended visits 
within the 22–26week window period. For MTX-naïve 
entry participants, observed 6-month remission rate was 
17.7%(95%CI 15.4%to20.2%) and estimated remission 
rate after imputation was 17%(95%CI 14.8%to19.4%) 
based on 1048 patients. For MTX-exposed patients, 
corresponding estimates were 3.5%(95%CI 2.6%to4.6%) 
and 3.2%(95%CI 2.4%to4.3%) based on observed data 
and imputed data from 1718 patients. The adjusted OR 
of achieving 6-month remission for MTX-exposed versus 
MTX-naïve patients was 0.26(95%CI 0.17to0.40). Adjust-
ments were made for variables included in the base 
logistic regression model.
Predictors of clinical remission at 6 months
MtX-naïve at entry
The base (multilevel) random effects logistic regression 
model for MTX-naïve entry patients is shown in online 
supplementary table 1. Age, sex, ethnicity, baseline 
DAS28 and randomised to concomitant glucocorticoids 
were associated with remission. After screening, three 
additional variables were considered in building the 
model further. These were functional disability (Health 
Assessment Questionnaire, HAQ), SF-36 Physical and 
Mental Summary Scores.
As HAQ was negatively correlated with SF-36 Physical 
Summary Score (Pearson correlation of −0.57), two final 
models (A and B; see table 2) were derived, in which 
either HAQ or SF-36 Physical Summary Score (but not 
both together), alongside the SF-36 Mental Summary 
Score, was considered for inclusion using forward selec-
tion. In these models, remission was predicted by being 
white, male, younger, randomised to concomitant gluco-
corticoids, having better functional/physical and mental 
health and lower DAS28, at baseline. Being randomised 
to concomitant glucocorticoids increased the odds of 
achieving remission by 4.0(95%CI 2.3to7.2) over not 
receiving glucocorticoids (model B), controlling for 
other variables. As most MTX-naïve entry subjects (93%) 
received MTX, an effect for receiving MTX during the 
trial could not be estimated, although it was adjusted for 
in the analysis.
MtX-exposed at entry 
The logistic regression (dropping trial-level random 
effects) in MTX-exposed patients (see table 3) identi-
fied lower baseline DAS28 and randomisation to MTX 
as being associated with achieving 6-month remission. 
However, patients with prior MTX exposure who were 
randomised to MTX reinitiation were significantly more 
likely (p<0.0001) to achieve remission than those contin-
uing on background MTX (adjusted OR 5.2 with 95%CI 
2.5 to 10.4). No evidence for functional/physical and 
mental health effects was found.
Characterising disease activity over 1 year of follow-up
Novel latent class mixed modelling of DAS28 suggested 
the clustering into three subpopulations/classes with 
differing trajectory profiles in both MTX-naïve and 
exposed baseline groups. No evidence to support inclu-
sion of trial-level random effects, random slopes or 
random quadratic effects was found and so the linear 
mixed models within latent classes contained only fixed 
effects and random intercepts.
MtX-naïve at entry
The three subpopulations identified (table 4 and figure 1; 
n=1137) corresponded to a fast improver group (class 
1; 8% of patients) who, on average, started with higher 
DAS28; a moderate improver group (class 2; 31.6%) who 
improved at around half the rate of fast improvers; and 
an inadequate responder group (class 3; 60.4%) with an 
improvement rate only 20% of that in class 1. On average, 
DAS28 of a typical patient with RA would improve by 3.91 
in the fast improvers, 2.02 in moderate improvers and 0.56 
in inadequate responders over 1 year of follow-up from trial 
entry.
Higher baseline HAQ was associated with having inade-
quate response. Men were more likely than women to be 
fast improvers compared with moderate improvers. Higher 
DAS28 over time in inadequate responders was associated 
with longer symptom duration (p=0.0136), non-white 
(p=0.0118) and higher HAQ over time (p<0.0001). In 
moderate improvers, not being randomised to glucocorti-
coids (p=0.0074) and higher HAQ over time (p<0.0001) 
were associated with higher DAS28. In fast improvers, only 
higher HAQ was associated with higher DAS28 (p<0.0001). 
The model’s entropy was 0.758, demonstrating good classi-
fication. A four-latent class model with the same variables 
gave lower entropy (0.711).
MtX-exposed at entry
The three subpopulations identified (table 5; figure 2; 
n=2148) corresponded to a fast improver group (class 
1; 9.4% of patients), although not as fast as the corre-
sponding MTX-naïve subpopulation; a group that 
showed initial improvement but then plateaued and 
slowly worsened (class 2; 43.4%); and a refractory group 
(class 3; 47.3%). On average, DAS28 of a typical patient 
with RA would improve by 3 in the fast improvers, 0.7 in 
the plateauing group and would worsen by 0.11 in those 
refractory over 1 year of follow-up.
The ‘plateauing’ group tended to include, on average, 
patients with lower baseline functional disability. Moreover, 
in this group, there was evidence to suggest that higher 
DAS28 associated with being non-white (p=0.0213). Wors-
ening DAS28 was associated with worsening functional 
disability over time, irrespective of subpopulation. In the 
refractory group, continuation of background MTX or 
receiving other csDMARDs as an initial treatment at trial 
entry was, on average, associated with increased disease 
activity (DAS28 increase of 0.51, p=0.0032 and 0.67, 
p=0.0017 respectively) over time.
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Table 2 Final logistic regression model A (including SF-36 summary scores to base model) and model B (including HAQ to 
base model) for clinical remission at 6months for MTX-naive subjects at entry
Predictors log(OR) SE of log(OR) OR 95% CI for OR p-value
Final Model A (inclusion of SF-36 summary components to base model) 
Intercept* – – – – –
Age at Entry, years −0.0249 0.0076 0.98 0.96 to 0.99 0.0010
Disease Duration, years −0.0033 0.0300 1.00 0.94 to 1.06 0.9125
Gender Male v Female 0.9793 0.1953 2.66 1.82 to 3.90 <0.0001
Ethnicity White v Rest 1.3489 0.4957 3.85 1.46 to 10.2 0.0065
DAS28-ESR at Baseline −0.3616 0.0891 0.70 0.58 to 0.83 <0.0001
Rheumatoid Factor Positivity Yes v No −0.1352 0.2016 0.87 0.59 to 1.30 0.5024
Randomised to MTX at start* Yes v No – – – – –
Randomised to or on csDMARD at 
start Yes v No 0.1809 0.2726 1.20 0.70 to 2.04 0.5070
Randomised to Glucocorticoids at 
start Yes v No 1.3375 0.2926 3.81 2.15 to 6.76 <0.0001
  On Background Glucocorticoids at 
start Yes v No 0.2478 0.4857 1.28 0.49 to 3.32 0.6099
  SF-36 Physical Summary Score 0.0423 0.0118 1.04 1.02 to 1.07 0.0003
  SF-36 Mental Summary Score 0.0209 0.0076 1.02 1.01 to 1.04 0.0063
Final Model B (Inclusion of HAQ to base model) 
  Intercept* – – – – –
  Age at Entry, years −0.0191 0.0075 0.98 0.97 to 1.00 0.0109
  Disease Duration, years −0.0032 0.0299 1.00 0.94 to 1.06 0.9157
  Gender Male v Female 0.8551 0.1945 2.35 1.61 to 3.44 <0.0001
  Ethnicity White v Rest 1.3756 0.4937 3.96 1.50 to 10.4 0.0053
  DAS28-ESR at Baseline −0.3489 0.0904 0.71 0.59 to 0.84 0.0001
  Rheumatoid Factor Positivity Yes 
v No −0.1352 0.2008 0.87 0.59 to 1.29 0.5009
  Randomised to MTX at start* Yes 
v No – – – – –
  Randomised or on csDMARD at 
start Yes v No 0.1789 0.2714 1.20 0.70 to 2.04 0.5097
  Randomised to Glucocorticoids at 
start Yes v No 1.3976 0.2920 4.05 2.28 to 7.17 <0.0001
  On Background Glucocorticoids at 
start Yes v No 0.3778 0.4829 1.46 0.57 to 3.76 0.4340
  HAQ −0.6325 0.1616 0.53 0.39 to 0.73 <0.0001
*Estimates and SE are not estimable. MTX usage during study has been adjusted for in models. Majority of MTX-naïve subjects at trial entry 
received MTX during study (93%).xMark as
csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28, DiseaseActivity Score 28; ESR, erythrocyte sedimentation 
rate; HAQ, Health AssessmentQuestionnaire; MTX, methotrexate.
The model’s entropy was 0.609, demonstrating 
modest classification. A four-latent class model iden-
tified an additional group (around 3.3% of patients) 
that showed rapid improvement over 3 months and 
then rebounded dramatically. Although this model had 
increased entropy (0.659), given the fourth group’s size 
and unusual pattern, the three-latent class model was 
preferred.
Model outputs
The models presented in tables 4 and 5 are useful for 
characterising disease activity over time into more homo-
geneous subpopulations and for identifying predictors 
of subpopulation membership and disease activity level. 
The models are also useful for calculating and updating 
the probabilities of a patient belonging to each of the 
subpopulations given their current value of DAS28 and 
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Table 3 Final logistic regression model for clinical remission at 6months for MTX-exposed subjects
Predictors log(OR) SE of log(OR) OR 95%CI for OR P values
Intercept – – – – –
Age at entry, years −0.0160 0.0124 0.98 0.96 to 1.01 0.1953
Disease duration, years −0.0105 0.0206 0.99 0.95 to 1.03 0.6109
Gender: male versus female 0.2935 0.3697 1.34 0.65 to 2.77 0.4271
Ethnicity: white versus rest −0.0511 0.4137 0.95 0.42 to 2.14 0.9017
DAS28-ESR at baseline −0.8228 0.1600 0.44 0.32 to 0.60 <0.0001
Rheumatoid factor positivity: yes versus no −0.5277 0.3214 0.59 0.31 to 1.11 0.1007
MTX use in trial
(Randomised to MTX, previous use) versus (not 
receiving, previous use) 1.6499 0.8252 5.21 1.03 to 26.2 0.0456
Background MTX continued versus (not 
receiving, previous use) 0.0126 0.7874 1.01 0.22 to 4.74 0.9873
Randomised to or on csDMARD at start: yes 
versus no 1.1721 0.8953 3.23 0.56 to 18.7 0.1905
On background glucocorticoids at start: yes 
versus no 0.1169 0.3299 1.12 0.59 to 2.15 0.7230
csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28, DiseaseActivity Score 28; ESR, erythrocyte sedimentation 
rate; MTX, methotrexate.
covariates and estimated parameters from the model 
(including estimated random patient-level effects).24 
This would be particularly useful in an adaptive trial as a 
new individual recruited could be assigned probabilities 
of belonging to each trajectory by a model that included 
all previously recruited individuals.
Furthermore, such models also allow subject-specific 
predictions of future DAS28 values for patients either 
given a particular trajectory subpopulation or averaged 
over all possible trajectory subpopulations. They would 
also allow population-averaged inference for particular 
subgroups of patients defined by the values of baseline 
covariates to inform, for example, national treatment 
guidelines for patients with RA.
dIsCussIOn
By means of a large industry-academic partnership, IPD 
from non-biological arms of 18 RA RCTs were amalga-
mated. These data on 3290 patients allowed a more 
definitive investigation into clinical predictors of remis-
sion, beyond a systematic literature review, through flex-
ible multivariate modelling and novel subgroup analyses 
using latent class mixed modelling methodology.
We did not aim to do an IPD meta-analysis in order 
to estimate a common treatment effect across multiple 
trials investigating the same treatment against the same 
control intervention. Instead, our goal was to treat this 
IPD study as an observational cohort in order to more 
comprehensively investigate the predictors of remission 
on a variety of non-biological treatments and to discover 
clinically meaningful subpopulations of patients with RA 
that could inform the future recruitment of RA patient 
types into trials and more stratified patient management.
Although patients in RCTs are generally considered 
to be poorly representative of those patients seen in the 
general RA clinic population (having higher levels of 
disease activity at entry and fewer and less severe comor-
bidities), they nevertheless represent a subpopulation of 
patients with RA with very real clinical need. Additionally, 
they represent a patient subpopulation in which treat-
ment management decisions would be made based on 
the patients’ arthritis symptoms and signs and not compli-
cated by comorbidities and the potential for interactions 
between the assigned treatments and the comorbidities.
We conducted separate analyses for MTX-naïve and 
MTX-exposed strata at trial entry, reflecting relatively 
early and more established disease, respectively. Unsur-
prisingly, the 6-month remission rate for MTX-naïve 
(majority then randomised to MTX) patients was substan-
tially higher (17% vs 3.5%) than for those with prior 
MTX exposure. Utilisation of a treat-to-target strategy, as 
is usual in clinical practice, may have increased the remis-
sion rate in this group further.
A major unmet need is identifying which patients with 
RA are more or less likely to achieve remission. Our 
results suggest that, in MTX-naïve entry patients with 
relatively early disease and high disease activity, baseline 
factors including age, gender, ethnicity, disease activity, 
mental health and physical functioning may help identify 
those with a higher or lower chance of achieving 6-month 
remission. While all these factors have been previously 
identified,14 26 27 we have confirmed them in a very large 
sample with the benefits of controlled trial conditions, 
not usually achievable with large observational studies. 
These factors should be considered stratifiers when 
designing future clinical trials and interpreting results of 
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Table 4 Latent class mixed model results for MTX-naïve 
entry subjects over 1-year follow-up
Predictors log(OR) SE P values
Multinomial class membership model 
Class 1 (fast improver) versus class 2 (moderate improver) 
Intercept –2.1947 0.4901 <0.0001
Sex: male 
versus female 0.8881 0.3065 0.0038
Baseline HAQ 0.3416 0.2902 0.2393
Class 3 (inadequate response) versus class 2 (moderate 
improver) 
Intercept –1.2339 0.6461 0.0561
Sex: male 
versus female 0.0128 0.2762 0.9629
Baseline HAQ 0.6174 0.2805 0.0277
Linear mixed 
model Estimate SE P values
Intercept 
Class 1 7.788 0.9264 <0.0001
Class 2 5.6199 0.3158 <0.0001
Class 3 5.7350 0.3400 <0.0001
Disease duration, years 
Class 1 –0.0083 0.0397 0.8335
Class 2 –0.0016 0.0104 0.8768
Class 3 0.0312 0.0126 0.0136
Ethnicity 
White versus 
rest: class 1 –0.5313 0.3882 0.1711
White versus 
rest: class 2 –0.2726 0.1837 0.1379
White versus 
rest: class 3 –0.4331 0.1719 0.0118
Follow-up 
time in study, 
weeks
Class 1 –0.2051 0.0221 <0.0001
Class 2 –0.1117 0.0080 <0.0001
Class 3 –0.0420 0.0080 <0.0001
Follow-up 
time squared
Class 1 0.0025 0.0004 <0.0001
Class 2 0.0014 0.0001 <0.0001
Class 3 0.0006 0.0002 <0.0001
Randomised to MTX at start 
Yes versus 
no: class 1 –1.2085 0.8352 0.1479
Yes versus 
no: class 2 –0.1143 0.2230 0.6082
Yes versus 
no: class 3
–0.1299 0.2181 0.5513
Continued
Linear mixed 
model Estimate SE P values
Randomised or on csDMARD at start 
Yes versus 
no: class 1 –0.0597 0.4436 0.8930
Yes versus 
no: class 2 –0.1673 0.1304 0.1993
Yes versus 
no: class 3 –0.1127 0.1303 0.3871
Randomised to glucocorticoids at start 
Yes versus 
no: class 1 –0.3899 0.3976 0.3267
Yes versus 
no: class 2 –0.3962 0.1480 0.0074
Yes versus 
no: class 3 –0.2540 0.1550 0.1013
On background glucocorticoid at start 
Yes versus 
no: class 1 –0.4879 0.3389 0.1500
Yes versus 
no: class 2 0.2907 0.2262 0.1987
Yes versus 
no: class 3 0.3468 0.2123 0.1024
HAQ (time varying) 
Class 1 0.4913 0.1045 <0.0001
Class 2 0.5564 0.0698 <0.0001
Class 3 0.6114 0.1035 <0.0001
Variance components* 
Variance 
of random 
intercept 0.6308 0.0506 <0.0001
Error SD 0.7941 0.0122 <0.0001
Relative 
entropy† 0.758
*Trial-levels random effects were investigated and found to be not 
necessary
†A relative entropy takes values between 0 and 1, with 1 indicating 
perfect classification
Table 4 Continued
biomarker studies. The potential role of mental health is 
of current interest, although mechanisms are uncertain, 
complex and bidirectional.26 28 29 The fact that mental 
and physical/functional well-being was predictive in 
MTX-naïve entry patients with relatively early disease but 
not in the prior MTX-exposed entry patients with more 
established disease is of note and should be explored 
further as it is difficult in our study to disentangle early/
established disease from no/previous exposure to MTX. 
Some previous studies have shown an effect of smoking 
status on disease activity14 30 we could not confirm this. 
However, our finding could be due to the high propor-
tion of systematically missing smoking data (57%). RF 
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Figure 1 Mean profiles over 1 year from the observed 
Disease Activity Score 28 (DAS28) data for patients who 
were methotrexate (MTX)-naïve at trial entry, after stratifying 
by predicted class membership. Class 1—fast improver 
group (red): 8%; class 2—moderate improver group (blue): 
31.6%; class3—inadequate response group (green): 60.4% 
(entropy: 0.758).
Table 5 Latent class mixed model results for MTX-
exposed subjects over 1-year follow-up
Predictors log(OR) SE P values
Multinomial class 
membership model
Class 1 (fast improver) versus 
class 2 (plateaued)
Intercept −1.7852 0.3187 <0.0001
Baseline HAQ 0.4137 0.2073 0.0460
Class 3 (refractory) versus 
class 2 (plateaued)
Intercept −0.7352 0.2987 0.0138
Baseline HAQ 0.5536 0.1648 0.0008
Linear mixed 
model Estimate SE P values
Intercept
Class 1 5.2433 0.6394 <0.0001
Class 2 5.7507 0.2552 <0.0001
Class 3 5.8371 0.2018 <0.0001
Ethnicity
White versus 
rest: class 1 –0.1746 0.1929 0.3655
White versus 
rest: class 2 –0.2380 0.1034 0.0213
White versus 
rest: class 3 –0.1233 0.0931 0.1852
Follow-up time 
in study, weeks
Class 1 –0.1668 0.0091 <0.0001
Class 2 –0.0863 0.0059 <0.0001
Class 3 –0.0030 0.0042 0.4697
Follow-up time 
squared
Class 1 0.0021 0.0001 <0.0001
Class 2 0.0014 0.0001 <0.0001
Class 3 0.0001 0.0001 0.1708
MTX use
(Randomised 
MTX, previous 
on) versus 
previous 
on but not 
randomised: 
class 1 1.0513 0.6129 0.0863
(Randomised 
MTX, previous 
on) versus 
previous 
on, but not 
randomised: 
class 2
0.0186 0.2750 0.9461
Continued
was not associated with remission here. Previous studies 
show conflicting results.14 31 32
We identified three distinct disease activity trajecto-
ries in both MTX-naïve entry and MTX-exposed strata. 
Although we have given trajectory classes similar names 
in both strata, the degree of improvement differed 
depending on MTX exposure history (or early vs estab-
lished disease at entry through confounding). Siemons et 
al33 also observed three distinct trajectories from an unad-
justed latent class mixed model analysis over the first year 
in patients with early RA.33 All their patients followed 
a treat-to-target strategy and 82% belonged to a ‘fast 
response’ group with only 3% in a ‘poor response’ group. 
They found evidence for differences across groups in 
baseline disease activity measures, pain and SF-36 Phys-
ical and Mental Health Summary Scores.33 However, they 
found weaker evidence to support a role of gender in 
distinguishing groups. We found gender and baseline 
functional disability were predictors of trajectory class in 
the MTX-naïve group. The latter was the lone predictor 
of class membership for MTX-exposed patients. However, 
the findings of Siemons et al were based on one-way 
analyses of variance rather than introducing variables 
into their latent class model. There has been debate on 
whether or not the incorporation of covariates may play 
an important role in enumerating classes.34
A number of variables were associated with DAS28 
levels within trajectory classes. In both MTX-naïve and 
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Linear mixed 
model Estimate SE P values
(Randomised 
MTX, previous 
on) versus 
previous 
on, but not 
randomised: 
class 3 0.3206 0.2381 0.1781
Background 
MTX continued 
versus 
previous 
on but not 
randomised: 
class 1 0.9683 0.6140 0.1148
Background 
MTX continued 
versus 
previous 
on but not 
randomised: 
class 2 0.0762 0.2430 0.7539
Background 
MTX continued 
versus 
previous 
on but not 
randomised: 
class 3 0.5088 0.1729 0.0032
Randomised or 
on csDMARD 
at start
Yes versus no: 
class 1 0.5336 0.6840 0.4353
Yes versus no: 
class 2 –0.1657 0.3004 0.5813
Yes versus no: 
class 3 0.6739 0.2151 0.0017
On 
background 
glucocorticoids 
at start
Yes versus no: 
class 1 –0.1578 0.1551 0.3088
Yes versus no: 
class 2 0.0648 0.0843 0.4419
Yes versus no: 
class 3 –0.1037 0.0788 0.1885
HAQ (time 
varying)
Class 1 0.3958 0.0601 <0.0001
Class 2 0.3773 0.0413 <0.0001
Class 3 0.2641 0.0313 <0.0001
Table 5 Continued
Continued
Linear mixed 
model Estimate SE P values
Variance 
components*
Variance 
of random 
intercept 0.6174 0.0269 <0.0001
Error SD 0.6902 0.0056 <0.0001
Relative 
entropy† 0.609
*Trial-level random effects were investigated and found to be not 
necessary.
†A relative entropy takes values between 0 and 1, with 1 indicating 
perfect classification.
csDMARD, conventional synthetic disease-modifying 
antirheumatic drug; HAQ, HealthAssessment Questionnaire; MTX, 
methotrexate.
Table 5 Continued
Figure 2 Mean profiles over 1 year from the observed 
Disease Activity Score 28 (DAS28) data for the methotrexate 
(MTX)-exposed patients after stratifying by predicted class 
membership. Class 1—fast improver group (red): 9.4%; 
class 2—moderate improver group (blue): 43.4%; class 
3—inadequate response group (green): 47.3% (entropy: 
0.609).
MTX-exposed patients, higher HAQ was associated with 
higher DAS28 in all classes. Interestingly, in the refrac-
tory class of MTX-exposed patients, those who continued 
background MTX or took other csDMARDs at trial start 
had higher DAS28 over time. In the class which plateaued, 
non-whites had higher DAS28 over time. Furthermore, 
non-whites had higher DAS28 within both moderate 
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improver and inadequate response trajectory classes of 
the MTX-naïve stratum.
It may seem somewhat confusing that lower disease 
activity at baseline was associated with achieving clin-
ical remission at 6 months in both baseline MTX-naïve 
and MTX-exposed groups, and yet there was a subpop-
ulation of baseline MTX-naïve patients who improved 
rapidly but started with, on average, higher levels of 
disease activity at baseline than the other two subpopula-
tions of MTX-naïve patients. However, when comparing 
two patients who differ at baseline with regard to only 
disease activity (with all other baseline covariates being 
the same), it is not surprising that the one with the lower 
baseline disease activity has a higher chance of attaining 
remission, presumably because he/she has less far to 
go to attain remission. By comparison, the MTX-naïve 
subpopulation of ‘fast improvers’ who started with the 
highest levels of disease activity and rapidly improved, 
differed from the other MTX-naïve subpopulations 
in terms of its gender and HAQ baseline distributions. 
That is, the ‘fast improvers’ had a higher proportion of 
men and, on average, had higher HAQ values than the 
other subgroups. Therefore, this ‘fast improvers’ group 
starts off with higher levels of disease activity and rapidly 
improves compared with the others primarily because 
it was made up of patients with a different profile of 
covariate values in terms of gender and HAQ. It is known 
that high levels of HAQ at baseline correlate positively 
with high levels of DAS28 at baseline and that men are 
more likely to achieve clinical remission at 6 months than 
women in the MTX-naïve subpopulation (table 2).
When interest is focused on early treatment response 
and its predictors, then approaches which restrict the 
longitudinal disease activity response to this early time 
period rather than the whole follow-up period may be 
more appropriate. Such approaches would be much 
more applicable to recent clinical trials in early disease in 
which aggressive treatment reflects the window of oppor-
tunity and treat-to-target goals.
There are many advantages of combining data from 
multiple trials. However, one methodological challenge 
is data harmonisation across trials; in particular here, 
with regard to creating a common DAS28 variable. There 
is ongoing debate as to the exact equivalence of DAS28 
calculated using different formulae and the validity of 
combining different methods of calculation in the same 
analysis. These issues could impact on findings, although 
we believe less so in characterising disease activity over 
time. There is also debate over the extent to which DAS28 
remission cut-off overestimates remission, as defined 
by absence of residual inflammatory disease activity.35 
However, DAS28 remission remains a widely used and 
aspirational target in clinical practice and trials, and we 
do not believe this invalidates our findings.
Even though our analyses were done using relatively 
large sample sizes, there is still the need to validate the 
findings before these results/models could be used 
to inform clinical practice or trial selection. There is a 
potential for our models to be overoptimistic due to the 
model fitting process and multiple testing. In addition, 
models which incorporate routinely collected biomarkers 
may have more clinical utility.
The existence of differing trajectories supports a strat-
ified medicine approach and suggests the potential for 
tailoring treatments to distinct patient subpopulations. 
Moreover, trajectories and predictors of response may 
differ by drug class. For example, these latent class mixed 
models would allow us, using the disease activity measure 
at screening (or past disease activity measures) and base-
line covariate information, to estimate the likely trajec-
tory pattern an MTX-naïve patient with high disease 
activity would take if they were to enter a trial and be 
randomised to a non-biological arm. If it was important, 
in this trial, to select only patients who had a high proba-
bility of responding to treatment, then our models could 
identify those patients who were least likely to respond 
(ie, the inadequate responders) to the control treat-
ment and exclude them from the trial. These types of 
models could also be used in clinical practice (when vali-
dated), for example, to assign a probability of response 
to different choices or combinations of csDMARDs by an 
MTX-naïve patient with active disease (assuming that the 
clinician had access to their past disease activity values 
and covariate information). The prediction of trajec-
tory class or the likely response to a change in treatment 
could be refined at follow-up visits using current disease 
activity values.
The entropies of our models, for both MTX-naïve and 
MTX-exposed strata, show room for improvement in 
classification accuracy. We anticipate that the addition 
of novel immune biomarkers, being investigated by the 
RA-MAP Consortium through their inception cohort 
study, will lead to predictor models that are clinically 
informative when choosing treatments for patients with 
RA.
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